Mutation scanning of the RET protooncogene using high-resolution melting analysis

Clinical Chemistry

Volumn 52, Issue 1, 2006, Pages 138-141

  Margraf, Rebecca L ^a,d   Mao, Rong ^a,b   Highsmith, W Edward ^c   Holtegaard, Leonard M ^c   Wittwer, Carl T ^a,b  

^a ARUP INSTITUTE FOR CLINICAL AND EXPERIMENTAL PATHOLOGY   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c MAYO CLINIC   (United States)

^d ARUP LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOUBLE STRANDED DNA;

AMPLICON; ARTICLE; EXON; GENE MUTATION; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOSITY; HIGH RESOLUTION MELTING ANALYSIS; HOMOZYGOSITY; HUMAN; MISSENSE MUTATION; NEUROFIBROMATOSIS; NUCLEOTIDE SEQUENCE; ONCOGENE RET; SIPPLE SYNDROME; THYROID MEDULLARY CARCINOMA;

GENOTYPE; HUMANS; MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROTO-ONCOGENE PROTEINS C-RET;

EID: 29744432126     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2005.052951     Document Type: Article

References (23)

1. Kambouris M, Jackson CE, Feldman GL. Diagnosis of multiple endocrine neoplasia [MEN] 2A, 2B and familial medullary thyroid cancer [FMTC] by multiplex PCR and heteroduplex analyses of RET proto-oncogene mutations. Hum Mutat 1996;8:64-70.
2. Ceccherini I, Hofstra RM, Luo Y, Stulp RP, Barone V, Stelwagen T, et al. DNA polymorphisms and conditions for SSCP analysis of the 20 exons of the ret proto-oncogene. Oncogene 1994;9:3025-9.
3. Kruckeberg KE, Thibodeau SN. Pyrosequencing technology as a method for the diagnosis of multiple endocrine neoplasia type 2. Clin Chem 2004;50: 522-9.
4. de la Fuente M, Quinteiro C, Dominguez F, Loidi L. LightCycler PCR assay for genotyping codon 634 mutations in the RET protooncogene. Clin Chem 2001;47:1131-2.
5. Ruiz A, Antinolo G, Marcos I, Borrego S. Novel technique for scanning of codon 634 of the RET protooncogene with fluorescence resonance energy transfer and real-time PCR in patients with medullary thyroid carcinoma. Clin Chem 2001;47:1939-44.
6. Xue F, Yu H, Maurer LH, Memoli VA, Nutile-McMenemy N, Schuster MK, et al. Germline RET mutations in MEN 2A and FMTC and their detection by simple DNA diagnostic tests. Hum Mol Genet 1994;3:635-8.
7. Kim IJ, Kang HC, Park JH, Ku JL, Lee JS, Kwon HJ, et al. RET oligonucleotide microarray for the detection of RET mutations in multiple endocrine neoplasia type 2 syndromes. Clin Cancer Res 2002;8:457-63.
8. Siegelman M, Mohabeer A, Fahey TJ III, Tomlinson G, Mayambala C, Jafari S, et al. Rapid, nonradioactive screening for mutations in exons 10, 11, and 16 of the RET protooncogene associated with inherited medullary thyroid carcinoma. Clin Chem 1997;43:453-7.
9. Blank RD, Sklar CA, Martin ML. Denaturing gradient gel electrophoresis to diagnose multiple endocrine neoplasia type 2. Clin Chem 1996;42:598-603.
10. Orban TI, Csokay B, Olah E. Sequence alterations can mask each other's presence during screening with SSCP or heteroduplex analysis: BRCA genes as examples. Biotechniques 2000;29:94-8.
11. Wittwer CT, Reed GH, Gundry CN, Vandersteen JG, Pryor RJ. High-resolution genotyping by amplicon melting analysis using LCGreen. Clin Chem 2003; 49:853-60.
12. Liew M, Pryor R, Palais R, Meadows C, Erali M, Lyon E, Wittwer C. Genotyping of single-nucleotide polymorphisms by high-resolution melting of small amplicons. Clin Chem 2004;50:1156-64.
13. Dobrowolski SF, McKinney JT, Amat di San Filippo C, Giak Sim K, Wilcken B, Longo N. Validation of dye-binding/high-resolution thermal denaturation for the identification of mutations in the SLC22A5 gene. Hum Mutat 2005;25: 306-13.
14. Willmore C, Holden JA, Zhou L, Tripp S, Wittwer CT, Layfield LJ. Detection of c-kit-activating mutations in gastrointestinal stromal tumors by high-resolution amplicon melting analysis. Am J Clin Pathol 2004;122:206-16.
15. Reed GH, Wittwer CT. Sensitivity and specificity of single-nucleotide polymorphism scanning by high-resolution melting analysis. Clin Chem 2004; 50:1748-54.
16. Eng C, Mulligan LM. Mutations of the RET proto-oncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic tumours, and Hirschsprung disease. Hum Mutat 1997;9:97-109.
17. Stenson PD, Ball EV, Mort M, Phillips AD, Shiel JA, Thomas NS, et al. Human Gene Mutation Database (HGMD): 2003 update. Hum Mutat 2003;21:577-81.
18. Ruiz A, Antinolo G, Fernandez RM, Eng C, Marcos I, Borrego S. Germline sequence variant S836S in the RET proto-oncogene is associated with low level predisposition to sporadic medullary thyroid carcinoma in the Spanish population. Clin Endocrinol (Oxf) 2001;55:399-402.
19. Elisei R, Cosci B, Romei C, Bottici V, Sculli M, Lari R, et al. RET exon 11 (G691S) polymorphism is significantly more frequent in sporadic medullary thyroid carcinoma than in the general population. J Clin Endocrinol Metab 2004;89:3579-84.
20. Borrego S, Saez ME, Ruiz A, Gimm O, Lopez-Alonso M, Antinolo G, et al. Specific polymorphisms in the RET proto-oncogene are over-represented in patients with Hirschsprung disease and may represent loci modifying phenotypic expression. J Med Genet 1999;36:771-4.
21. Steve Rozen S, Skaletsky HJ. Primer3 on the WWW for general users and for biologist programmers. In: Krawetz S, Misener S, eds. Bioinformatics methods and protocols: methods in molecular biology. Totowa, NJ: Humana Press, 2000:365-86. [Source code available at: http://fokker.wi.mit.edu/primer3/ (accessed October 10, 2005)].
22. Breslauer KJ, Frank R, Blocker H, Marky LA. Predicting DNA duplex stability from the base sequence. Proc Natl Acad Sci U S A 1986;83:3746-50.
23. Peyret N, Seneviratne PA, Allawi HT, SantaLucia J Jr. Nearest-neighbor thermodynamics and NMR of DNA sequences with internal A.A, C.C, G.G, and T.T mismatches. Biochemistry 1999;38:3468-77.